The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II study with trabedersen (AP 12009) monotherapy for the treatment of patients with advanced pancreatic cancer, malignant melanoma, and colorectal carcinoma.
H. Oettle
No relevant relationships to disclose
A. Hilbig
Other Remuneration - Antisense Pharma
T. Seufferlein
No relevant relationships to disclose
A. Tsianakas
No relevant relationships to disclose
T. Luger
No relevant relationships to disclose
R. M. Schmid
No relevant relationships to disclose
G. von Wichert
No relevant relationships to disclose
E. Endlicher
No relevant relationships to disclose
C. Garbe
No relevant relationships to disclose
K. K. Kaehler
No relevant relationships to disclose
A. Hauschild
No relevant relationships to disclose
A. Enk
No relevant relationships to disclose
P. Kiessling
Employment or Leadership Position - Antisense Pharma
S. Schmaus
Employment or Leadership Position - Antisense Pharma
H. Heinrichs
Employment or Leadership Position - Antisense Pharma
Stock Ownership - Antisense Pharma
K. Schlingensiepen
Employment or Leadership Position - Antisense Pharma
Stock Ownership - Antisense Pharma